Near-uniform, low-level conjugation of cytotoxins to antitumor antibodies increases their tolerability without compromising efficacy.
References
Carter, P.J. & Senter, P.D. Cancer J. 14, 154–169 (2008).
Wu, A.M. & Senter, P.D. Nat. Biotechnol. 23, 1137–1146 (2005).
Lambert, J.M. Curr. Opin. Pharmacol. 5, 543–549 (2005).
Damle, N.K. Expert Opin. Biol. Ther. 4, 1445–1452 (2004).
Junutula et al. Nat. Biotechnol. 26, 925–932 (2008).
Sun, M.M. et al. Bioconjug. Chem. 16, 1282–1290 (2005).
McDonagh, C.F. et al. Protein Eng. Des. Sel. 7, 299–307 (2006).
Hamblett, K.J. et al. Clin. Cancer Res. 10, 7063–7070 (2004).
Scott, A.M. et al. J. Clin. Oncol. 26, Abstract 3025, presented at the 44th annual ASCO meeting, Chicago, IL, May 30–June 3, 2008.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Damle, N. Antibody-drug conjugates ace the tolerability test. Nat Biotechnol 26, 884–885 (2008). https://doi.org/10.1038/nbt0808-884
Issue Date:
DOI: https://doi.org/10.1038/nbt0808-884
- Springer Nature America, Inc.
This article is cited by
-
Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability
Pharmaceutical Research (2015)
-
Strategies and challenges for the next generation of therapeutic antibodies
Nature Reviews Immunology (2010)